rs121434292 — SLC39A4 Arg95Cys

Pathogenic missense variant in ZIP4, the primary intestinal zinc transporter, causing autosomal recessive acrodermatitis enteropathica — a treatable zinc malabsorption disorder

See your personal result for SLC39A4

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC39A4 Arg95Cys — The Gateway for Zinc

Your small intestine contains a protein called ZIP4, encoded by SLC39A4, that acts as the primary gateway for absorbing dietary zinc. ZIP4 sits on the apical (luminal) surface of enterocytes in the duodenum and jejunum, where it actively transports zinc ions from food into the intestinal wall — the first step in getting zinc from your plate into your bloodstream. Without a functioning ZIP4, dietary zinc passes through the gut essentially unabsorbed, no matter how much you eat.

The Arg95Cys variant (rs121434292) is a single-letter change at position 283 of the SLC39A4 coding sequence (c.283C>T), replacing arginine with cysteine at protein position 95. This missense substitution disrupts the ZIP4 protein structure and causes acrodermatitis enteropathica11 acrodermatitis enteropathica
AE: a rare inherited zinc malabsorption disorder first described in 1942. It is distinct from dietary zinc deficiency — it is a genetic inability to absorb zinc from food regardless of intake, an autosomal recessive disorder first linked to SLC39A4 in a landmark 2002 study22 a landmark 2002 study
Wang K et al. A novel member of a zinc transporter family is defective in acrodermatitis enteropathica. Am J Hum Genet, 2002.

The Mechanism

ZIP4 is not a simple channel — it is a regulated transporter that dynamically shuttles between the enterocyte membrane and intracellular compartments depending on zinc availability. When dietary zinc is plentiful, ZIP4 is endocytosed and held inside the cell; when zinc is scarce, ZIP4 moves to the apical membrane to maximize absorption. This feedback loop keeps systemic zinc levels stable across a wide range of dietary intakes.

The Arg95 residue lies within the large extracellular domain of ZIP4, which is critical for correct protein folding and membrane trafficking. Functional studies of related AE missense mutations by Wang et al. 200433 Wang et al. 2004
Wang F et al. Acrodermatitis enteropathica mutations affect transport activity, localization and zinc-responsive trafficking of the mouse ZIP4 zinc transporter. Hum Mol Genet, 2004 demonstrated that all tested AE-associated missense variants either abolish zinc transport activity outright or impair zinc-responsive endocytosis. Arg95Cys-type substitutions in the extracellular domain are expected to disrupt protein folding and prevent correct trafficking to the cell surface — a class of defect that effectively silences the transporter.

The Evidence

Arg95Cys was first reported by Nakano et al. 200344 Nakano et al. 2003
Nakano A et al. Novel SLC39A4 mutations in acrodermatitis enteropathica. J Invest Dermatol, 2003 in Japanese twins presenting with the classical AE triad of periorificial dermatitis, diarrhea, and alopecia. The twins carried Arg95Cys in compound heterozygosity with a 53-bp insertion creating a premature stop codon — a typical presentation for AE, where patients are rarely true homozygotes but instead carry two different loss-of-function alleles. The mutation was absent from 100 control chromosomes screened in the same study, supporting pathogenicity.

The variant is recorded in ClinVar as Pathogenic/Likely pathogenic (VCV000003722, 2-star review, multiple submitters, no conflicts, last evaluated January 2025). It is exceptionally rare in population databases: gnomAD exomes record only 9 heterozygous carriers among 685,748 individuals screened (allele frequency ~6.6 × 10⁻⁶), with no homozygotes identified — consistent with a highly penetrant recessive disorder causing early-onset illness in the rare individuals who inherit two loss-of-function alleles.

AE itself occurs at approximately 1 in 500,000 newborns globally, though the true incidence may be higher due to misdiagnosis as nutritional zinc deficiency or other skin conditions. Without genetic confirmation and zinc supplementation, the disorder can progress to severe immune dysfunction, growth failure, neurological complications, and historically even death. With lifelong zinc supplementation, the prognosis is excellent — clinical response typically begins within days and is essentially complete.

Practical Actions

For heterozygous carriers (AG genotype): no treatment is needed. Heterozygous carriers have one functional copy of SLC39A4 and one defective copy. The single working copy provides sufficient ZIP4 activity to maintain normal zinc absorption and serum zinc levels. Carriers are clinically unaffected. The primary significance of carrier status is reproductive risk: if both parents carry a pathogenic SLC39A4 variant, each pregnancy has a 25% chance of inheriting two defective copies and developing AE.

For homozygous or compound heterozygous individuals (AA or biallelic variants): the cornerstone of treatment is lifelong oral zinc supplementation starting at 3 mg/kg/day of elemental zinc, with most children ultimately maintained at 1-3 mg/kg/day. Zinc sulfate is the most widely used formulation; zinc gluconate and zinc acetate are alternatives for those who experience gastrointestinal irritation from sulfate. Because zinc and copper share the same absorption pathway (metallothionein induction), chronic high-dose zinc supplementation can cause copper deficiency — serum copper and zinc should both be monitored every 3-6 months, with dose adjusted to the lowest level maintaining normal serum zinc (70-120 µg/dL).

Interactions

Acrodermatitis enteropathica is caused by compound heterozygosity for two different pathogenic SLC39A4 alleles in the great majority of cases — true Arg95Cys homozygotes are rarely reported. Any individual identified as an Arg95Cys carrier who develops AE symptoms should have both SLC39A4 alleles fully sequenced to identify the second pathogenic variant, which may be a different missense, nonsense, frameshift, splice-site, or structural variant in the gene.

There are no well-documented interactions between rs121434292 and variants in other zinc transporter genes (SLC30A1-10, SLC39A1-14) that meaningfully alter clinical management for carriers. The clinical ZIP4 deficiency state in homozygotes is profound enough that other transporter variants do not compensate.

Nutrient Interactions

zinc reduced_absorption

Genotype Interpretations

What each possible genotype means for this variant.

GG Non-Carrier Normal

No SLC39A4 Arg95Cys variant detected — normal ZIP4 function

With two copies of the reference allele, both copies of your ZIP4 transporter fold correctly, traffic to the apical enterocyte membrane in response to low zinc, and efficiently absorb dietary zinc from the duodenum and jejunum. There is no increased risk of zinc malabsorption or acrodermatitis enteropathica from this genotype.

Zinc remains an essential micronutrient requiring adequate dietary intake (8-11 mg/day for adults), but your absorption machinery works as intended. Oysters, red meat, poultry, beans, nuts, and whole grains are good dietary sources.

AG Carrier Carrier

Heterozygous carrier of Arg95Cys — one working SLC39A4 copy, no zinc malabsorption

Acrodermatitis enteropathica follows autosomal recessive inheritance, meaning both SLC39A4 alleles must be non-functional for the disease to manifest. As a heterozygous carrier, you retain one fully functional ZIP4 transporter, which is sufficient for normal intestinal zinc absorption. Case series consistently document that parents of AE patients — who are obligate heterozygous carriers — show normal zinc levels, normal skin, and no gastrointestinal symptoms.

The Arg95Cys allele has a gnomAD exome frequency of approximately 6.6 × 10⁻⁶ globally, with the highest frequency observed in East Asian populations (~9 × 10⁻⁵ from the 38KJPN Japanese dataset), consistent with the original report in Japanese twins. Carrier frequency in the general European population is estimated at fewer than 1 in 100,000 individuals for this specific allele.

AA Homozygous Homozygous

Homozygous for Arg95Cys — consistent with acrodermatitis enteropathica requiring lifelong zinc supplementation

With two copies of the Arg95Cys allele (or biallelic SLC39A4 loss-of-function), ZIP4 protein function is abolished or severely impaired. Dietary zinc passes through the intestinal lumen without being absorbed, regardless of intake. Systemic zinc deficiency ensues, affecting essentially every organ system: zinc is required for over 300 enzymatic reactions, immune cell development, epithelial barrier integrity, wound healing, and neurodevelopment.

The classic triad of AE is periorificial and acral dermatitis, diarrhea, and alopecia, typically presenting in infancy after weaning from breast milk (which may contain enough bioavailable zinc to mask symptoms). Untreated or undertreated AE causes immune dysfunction, growth failure, delayed puberty, neurological disturbances, and was historically associated with premature death.

The response to oral zinc supplementation is dramatic — most patients show clear clinical improvement within days to weeks. Treatment is lifelong and essentially curative provided consistent adherence. Zinc sulfate is the standard formulation; serum zinc should be maintained within the normal reference range (70-120 µg/dL) using the lowest effective dose to prevent copper deficiency from competitive absorption inhibition.